Phase 1, Multicenter, Open-Label, Parallel Group Adaptive Pharmacokinetic Single Dose Study Of ISIS 681257 Subcutaneous Injections In Male And Female Subjects With Normal And Impaired Renal Function
Phase of Trial: Phase I
Latest Information Update: 24 May 2019
Price : $35 *
At a glance
- Drugs Pelacarsen (Primary)
- Indications Hyperlipoproteinaemia
- Focus Pharmacokinetics
- Sponsors Akcea Therapeutics
- 20 May 2019 Status changed from recruiting to completed.
- 23 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Jan 2019.
- 26 Apr 2018 New trial record